-+ 0.00%
-+ 0.00%
-+ 0.00%

The FDA Grants Fast Track Designation For Kymera Therapeutics' KT-621 For Moderate to Severe Asthma

Benzinga·04/13/2026 11:03:54
Listen to the news
  • KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027
  • KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027
  • Fast Track designation previously granted for KT-621 for moderate to severe AD